Shares of China-based immuno-oncology-focussed biotech I-Mab Biopharma (Nasdaq: IMAB) plunged more than 13% to $6.90 yesterday, after the company revealed in a filing with the Securities and Exchange Commissions that AbbVie (NYSE: ABBV) has discontinued a Phase I trial of I-Mab's anti-CD47 monoclonal antibody lemzoparlimab, which the US pharma major in-licensed for an upfront $180 million 2020.
The parties will continue to collaborate on the global development of anti-CD47 antibody therapy under the agreement. I-Mab will be eligible to receive, and AbbVie will pay, up to $1.295 billion in the development, regulatory and sales milestone payments, and the tiered royalties at rates from mid-to-high single digit percentages on global net sales outside of Greater China for certain new anti-CD47 antibodies currently in development, or the original milestone payments and tiered royalties previously disclosed in the company’s Form 20-F for the fiscal year 2021 for other licensed products. I-Mab has the exclusive right to develop and commercialize all licensed products under the agreement in Greater China.
AbbVie will discontinue the global Phase Ib study of lemzoparlimab combination therapy with azacitidine (AZA) and venetoclax, in patients with myelodysplastic syndrome (MDS) and acute myelocytic leukemia (AML). This decision was not based on any specific or unexpected safety concerns.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze